Mizoribine: A New Approach in the Treatment of Renal Disease

Table 4

Comparison between clinical stages in the three groups at the time of the first renal biopsy and the most recent follow-up examination.

	First renal biopsy			Most recent follow-up examination
	PWD (𝑛=21)	PWD-pulse (𝑛=20)	PWDM (𝑛=20)	PWD (𝑛=21)	PWD-pulse (𝑛=20)	PWDM (𝑛=20)
Stage 0	0/21 (0%)	0/20 (0%)	0/20 (0%)	2/21 (10%)^(e)	3/20 (15%)^(f)	12/20 (60%)^(e,f)
Stage 1	0/21 (0%)	0/20 (0%)	0/20 (0%)	7/21 (35%)	6/20 (30%)	7/20 (35%)
Stage 2	17/21 (81%)^(a)	14/20 (70%)^(a,b)	15/20 (75%)^(b)	11/21 (52%)^(g)	8/20 (40%)^(h)	1/20 (5%)^(g,h)
Stage 3	4/21 (19%)^(c)	6/20 (30%)^(c,d)	5/20 (25%)^(d)	1/21 (5%)^(i)	3/20 (15%)^(i,j)	0/20 (0%)^(j)

^(e,f,g,h)𝑃<.05.
^{(a,b,c,d,i,j)}n.s.: not significant.